Publisher:
Telstra
Name:
Telstra - EME research and science monitoring - Consumer advice
Copyrighted By:
Telstra
Family Friendly:
Yes
Language:
English
Skip to main content
Telstra Home Page
  • Personal
    Personal Home
    • Plans & devices

      • Mobiles

        • Mobiles on a plan
        • SIM only plans
        • Outright devices
        • Pre-Paid
        • 5G Phones
        • Explore mobiles
      • Tablets

        • Tablets on a plan
        • Pre-Paid
        • Explore tablets
      • Home phones

      • Roaming

      • Accessories

      • Deals

      • Shop by Brand

        • Apple
        • Samsung
        • Google
      • I want to I want to

        • Pay a bill
        • Upgrade my plan
        • Check my usage
        • Recharge Pre-Paid
        • Track my order
        • Activate my mobile
        • Trade-in my device
    • Internet

      • Home broadband

        • Internet plans
        • nbn plans
        • 5G Home Internet
        • Entertainment packages
        • Explore home broadband
      • Mobile broadband

        • Modems on a plan
        • SIM only data plans
        • Pre-Paid
        • Explore mobile broadband
      • Internet extras

        • Wi-Fi Booster
        • Explore internet extras
      • Cyber security and safety

        • Device Protect
        • Explore cyber security and safety
      • Platinum support

      • Deals

      • I want to I want to

        • Move house
        • See plan details
        • Switch to nbn
        • See nbn network speeds
        • Change plan
        • Pay a bill
        • Track my order
        • Request an extension
    • Entertainment

      • TV & movies

        • Disney+
        • Binge
        • Flash
        • Foxtel Now
        • Telstra TV
        • Telstra TV Box Office
        • Foxtel from Telstra
        • Explore TV & movies
      • Gaming

        • Xbox All Access
        • Xbox Game Pass
        • Game Optimiser
        • Explore gaming
      • Entertainment

        • Entertainment packages
        • Explore entertainment
      • Sport

        • Kayo
        • Explore sport
      • I want to I want to

        • Check my account
        • Go to Telstra Plus
        • Set up Telstra TV
        • Track my order
        • Pay a bill
    • Coverage & services

      • Telstra Plus

        • Sign in
        • All Ticket offers
        • Movie Tickets
        • Explore Telstra Plus
      • My Telstra

      • Coverage maps

      • Cyber security and safety

        • Device Protect
        • Explore cyber security and safety
      • Our network

        • What is 5G?
        • Our 5G network
        • 4GX
        • Regional services
        • Explore our network
      • Telstra Air®

        • About Telstra Air
        • Explore Telstra Air
      • Platinum support

        • Technical support types
        • Explore Telstra Platinum
      • I want to I want to

        • Go to My Telstra
        • Go to Webmail
        • See coverage maps
        • Track my order
        • Go to Telstra Plus
        • Pay a bill
        • Request an extension
    • Telstra Plus

    • Support

      • Personal Support

        • Accounts and billing
        • Internet
        • Mobiles and devices
        • Telstra Mail
        • Pre-Paid Services
        • Phone line
        • Entertainment and sport
        • Explore support
      • Support homepages

        • Personal
        • Business
        • Enterprise
        • Explore support
      • I want to I want to

        • Download My Telstra app
        • Find a store
        • Sign in to webmail
        • Understand my charges
        • Make a payment
        • Fix an internet issue
    • Contact us

      • Contact Us

        • Accounts and billing
        • Set up & technical support
        • Products, plans and services
        • Feedback and complaints
        • Multilingual services
        • Find a store
        • Explore contact us
    • Search in Telstra.com
  • Business
    Business Home
    • Plans & devices

      • Mobiles

        • Mobiles on a plan
        • 5G plans & devices
        • Explore mobiles
      • SIM plans

        • Mobile SIM plans
        • Tablet SIM plans
      • Tablets

        • Tablets on a plan
        • iPads
        • Mobile Worksuite
        • Explore tablets
      • Office phones

      • Shop by brand

        • Apple iPhones
        • Samsung mobiles
        • Microsoft
      • I want to I want to

        • Pay bill
        • Request payment extension
        • Book an appointment
        • Check my data usage
        • Change your plan
        • Move my mobile service to Telstra
        • Manage account online
        • Get account management support
    • Business internet

      • Broadband

        • nbn plans
        • nbn speeds
        • 5G Internet plan
        • ADSL plan
        • Explore Broadband
      • Unified Communications

      • Business-grade fibre

      • Mobile broadband

        • Data plans
        • Devices
        • Explore mobile broadband
      • Telstra Air

      • I want to I want to

        • Get a call back for nbn upgrade
        • Pay bill
        • Request payment extension
        • Set up Direct Debit
        • Move premises
        • Manage account online
        • Get account management support
    • Business solutions

      • Software

        • Microsoft 365
        • MYOB Business
        • Check Point Harmony Mobile
        • Telstra Calling for Office 365
        • Explore software
      • Go Digital

        • Get connected
        • Engage online
        • Protect your business
        • Business software
        • Explore Go Digital
      • Business services

        • Cyber Security Services
        • Business Website Services
        • Go Digital Consult
        • Tech Services
        • Telstra Data Protect
        • Explore Services
      • Tyro EFTPOS

      • I want to I want to

        • Book a Go Digital Consult
        • Sign up for Apps Marketplace
        • Log in to Apps Marketplace
        • Call Telstra Tech Services
        • Access Managing Risks report
        • Call Cyber Security Services
    • Internet of Things

      • Internet of Things

        • IoT SIM plans
        • Asset Tracking
        • Vehicle tracking
        • Site monitoring
        • Internet of Things homepage
      • I want to I want to

        • Pay bill
        • Request payment extension
        • Set up Direct Debit
        • Download bill
        • Manage my data
        • Manage account online
        • Get account management support
    • Telstra Plus

    • Support

      • Business Support

        • Account Management
        • Accounts & payments
        • Mobiles & devices
        • Internet & office phones
        • Business software
        • Explore Business Support
      • Outages

      • Support homepages

        • Personal
        • Business
        • Enterprise
    • Contact us

      • Sales

        • Call 13 2000
        • Sales
      • Accounts and billing

        • Call 13 2000
        • Accounts and billing
      • Concierge tech support

        • Call 13 2999
        • Concierge tech support
      • nbn

        • Call 13 2000
        • nbn
      • Other Options

        • Multilingual services
        • Business Technology Centres
    • Search in Telstra.com
  • Enterprise
    Enterprise Home
    • Products

      • Networks

        • Adaptive Networks
        • Software Defined Networks
        • Networks
      • Security

        • Secure your business
        • Safeguard your clouds
        • Protect your team
        • Security
      • Mobility Solutions

        • Enterprise 5G
        • Plans & Devices
        • Business Apps
        • Messaging & APIs
        • Mobility Solutions
      • Unified Communications

        • Calling and productivity
        • Conferencing
        • Customer Contact
        • Unified Communications
      • Cloud

        • Advice on Cloud
        • Cloud Connectivity
        • Cloud Solutions
        • Managed & Optimise Cloud
        • Security for Cloud
        • Cloud
      • Internet of Things

        • Capabilities
        • Solutions
        • Internet of Things
    • Services

      • Professional Services

        • Telstra Purple
      • Managed Services

        • Managed Collaboration
        • Managed Cost Optimisation
        • Managed Mobility
        • Managed Networks
        • Managed Services
    • Industries

      • Supply chain

        • Supply chain
      • Broadcast Media

        • Australian Media Networks
        • Broadcast Plus
        • Global Media Networks
        • Broadcast Media
      • Government

        • Federal
        • State
        • Local
        • Government
      • Mining & Resources

        • Mining Services
    • Channel Partners

      • Channel Partners

        • Register your interest
        • Telstra Partner Central
        • Channel Partners
    • Accounts

      • Policies

        • Financial Hardship Policy
    • Why Telstra

      • Why Telstra

        • Innovation and Experience
        • Global capabilities
        • Why Telstra
      • World-class networks

        • 5G
        • IoT
        • Global networks
        • World-class networks
    • News & Research

      • News & Research

        • Podcasts
        • Customer stories
        • News & Research
      • Events

        • Telstra Vantage Remixed
        • Events
    • Support

      • Enterprise Support

        • Accounts & Services
        • Billing & Payments
        • Enterprise Support
      • Self-service

        • Telstra Connect
        • Order Express
    • Contact us

      • Contact us

        • Request a callback
        • Expert Finder
        • Contact us
    • Search in Telstra.com
  • Telstra Plus
  • Help
  • Search
  • Cart
  • Sign in
    • My Telstra
    • Business Account
    • Telstra Connect
    • Telstra Plus
    • Telstra Mail
    Sign in
    • My Telstra
    • Business Account
    • Telstra Connect
    • Telstra Plus
    • Telstra Mail
Search suggestions will appear below the field as you type

Take me to

  • Apple watch
  • Prepaid recharge
  • Change of ownership
  • Apple airpods
  • Webmail
No results found

Take me to

  1. < Personal Home >
  2. < Consumer Advice >
  3. < Electromagnetic energy (EME) >

EME research and science monitoring

  • Telstra has maintained an EME research group since 1984 as part of our commitment to understanding any possible health effects from EME.

    In 2004, Telstra altered its approach to participate in a consortium of leading Australian research institutions to establish a Centre of Excellence in Radio Frequency (RF) EME Research, known as the Australian Centre for RF Bioeffects Research (ACRBR). This centre was funded by the National Health and Medical Research Council (NHMRC). In 2013 a new Centre of Excellence was established called the Australian Centre for Electromagnetic Bioeffects Research (ACEBR). This centre was refunded again in 2019 for a further five-year period.

    As part of the ACEBR, our ongoing commitment to EME research is also maintained through joint funding of a state-of-the-art RF laboratory at Swinburne University and provision of mobile telecommunications equipment, to support work on RF dosimetry (measurement).

    While Telstra actively participates in EME research to understand the outcomes, we do not conduct the health risk assessments from the research. The health risk assessments are conducted by the national and international health agencies.

    Telstra's ongoing involvement with EME research reflects the importance we place on ensuring the safety of our customers, employees and the public.

  • IARC CLASSIFIES RADIOFREQUENCY ELECTROMAGNETIC FIELDS AS POSSIBLY CARCINOGENIC TO HUMANS

    Lyon, France, May 31, 2011 - The WHO/International Agency for Research on Cancer (IARC) has classified radiofrequency electromagnetic fields as possibly carcinogenic to humans (Group 2B), based on an increased risk for glioma, a malignant type of brain cancer1, associated with wireless phone use.

    From May 24–31 2011, a Working Group of 31 scientists from 14 countries has been meeting at IARC in Lyon, France, to assess the potential carcinogenic hazards from exposure to radiofrequency electromagnetic fields. These assessments will be published as Volume 102 of the IARC Monographs, which will be the fifth volume in this series to focus on physical agents, after Volume 55 (Solar Radiation), Volume 75 and Volume 78 on ionizing radiation (X-rays, gamma-rays, neutrons, radio-nuclides), and Volume 80 on non-ionizing radiation (extremely low-frequency electromagnetic fields).

    The IARC Monograph Working Group discussed the possibility that these exposures might induce long-term health effects, in particular an increased risk for cancer. This has relevance for public health, particularly for users of mobile phones, as the number of users is large and growing, particularly among young adults and children.

    The IARC Monograph Working Group discussed and evaluated the available literature on the following exposure categories involving radiofrequency electromagnetic fields:

    • occupational exposures to radar and to microwaves;
    • environmental exposures associated with transmission of signals for radio, television and wireless telecommunication; and
    • personal exposures associated with the use of wireless telephones.

    International experts shared the complex task of tackling the exposure data, the studies of cancer in humans, the studies of cancer in experimental animals, and the mechanistic and other relevant data.

    Results

    The evidence was reviewed critically, and overall evaluated as being limited2 among users of wireless telephones for glioma and acoustic neuroma, and inadequate3 to draw conclusions for other types of cancers. The evidence from the occupational and environmental exposures mentioned above was similarly judged inadequate. The Working Group did not quantitate the risk; however, one study of past cell phone use (up to the year 2004), showed a 40% increased risk for gliomas in the highest category of heavy users (reported average: 30 minutes per day over a 10-year period).

    Conclusions

    Dr Jonathan Samet (University of Southern California, USA), overall Chairman of the Working Group, indicated that "the evidence, while still accumulating, is strong enough to support a conclusion and the 2B classification. The conclusion means that there could be some risk, and therefore we need to keep a close watch for a link between cell phones and cancer risk."

    "Given the potential consequences for public health of this classification and findings," said IARC Director Christopher Wild, "it is important that additional research be conducted into the long-term, heavy use of mobile phones. Pending the availability of such information, it is important to take pragmatic measures to reduce exposure such as hands-free devices or texting."

    The Working Group considered hundreds of scientific articles; the complete list will be published in the Monograph. It is noteworthy to mention that several recent in-press scientific articles4 resulting from the Interphone study were made available to the working group shortly before it was due to convene, reflecting their acceptance for publication at that time, and were included in the evaluation.

    A concise report summarizing the main conclusions of the IARC Working Group and the evaluations of the carcinogenic hazard from radiofrequency electromagnetic fields (including the use of mobile telephones) will be published in The Lancet Oncology in its July 1 issue, and in a few days online.

    • For more information, please contact:Dr Kurt Straif, IARC Monographs Section, at +33 472 738 511, or straif@iarc.fr
    • Dr Robert Baan, IARC Monographs Section, at +33 472 738 659, or baan@iarc.fr
    • Nicolas Gaudin, IARC Communications Group, at +33 472 738 478, or com@iarc.fr
    • Briefing Audio File

    About IARC

    The International Agency for Research on Cancer (IARC) is part of the World Health Organization. Its mission is to coordinate and conduct research on the causes of human cancer, the mechanisms of carcinogenesis, and to develop scientific strategies for cancer control. The Agency is involved in both epidemiological and laboratory research and disseminates scientific information through publications, meetings, courses, and fellowships.

    ABOUT THE IARC MONOGRAPHS

    What are the IARC Monographs?

    The IARC Monographs identify environmental factors that can increase the risk of human cancer. These include chemicals, complex mixtures, occupational exposures, physical and biological agents, and lifestyle factors. National health agencies use this information as scientific support for their actions to prevent exposure to potential carcinogens. Interdisciplinary working groups of expert scientists review the published studies and evaluate the weight of the evidence that an agent can increase the risk of cancer. The principles, procedures, and scientific criteria that guide the evaluations are described in the Preamble to the IARC Monographs. Since 1971, more than 900 agents have been evaluated, of which approximately 400 have been identified as carcinogenic or potentially carcinogenic to humans.

    Definitions
    Group 1: The agent is carcinogenic to humans.

    This category is used when there is sufficient evidence of carcinogenicity in humans. Exceptionally, an agent may be placed in this category when evidence of carcinogenicity in humans is less than sufficient but there is sufficient evidence of carcinogenicity in experimental animals and strong evidence in exposed humans that the agent acts through a relevant mechanism of carcinogenicity.

    Group2

    This category includes agents for which, at one extreme, the degree of evidence of carcinogenicity in humans is almost sufficient, as well as those for which, at the other extreme, there are no human data but for which there is evidence of carcinogenicity in experimental animals. Agents are assigned to either Group 2A (probably carcinogenic to humans) or Group 2B (possibly carcinogenic to humans) on the basis of epidemiological and experimental evidence of carcinogenicity and mechanistic and other relevant data. The terms probably carcinogenic and possibly carcinogenic have no quantitative significance and are used simply as descriptors of different levels of evidence of human carcinogenicity, with probably carcinogenic signifying a higher level of evidence than possibly carcinogenic.

    Group 2A: The agent is probably carcinogenic to humans.

    This category is used when there is limited evidence of carcinogenicity in humans and sufficient evidence of carcinogenicity in experimental animals. In some cases, an agent may be classified in this category when there is inadequate evidence of carcinogenicity in humans and sufficient evidence of carcinogenicity in experimental animals and strong evidence that the carcinogenesis is mediated by a mechanism that also operates in humans. Exceptionally, an agent may be classified in this category solely on the basis of limited evidence of carcinogenicity in humans. An agent may be assigned to this category if it clearly belongs, based on mechanistic considerations, to a class of agents for which one or more members have been classified in Group 1 or Group 2A.

    Group 2B: The agent is possibly carcinogenic to humans.

    This category is used for agents for which there is limited evidence of carcinogenicity in humans and less than sufficient evidence of carcinogenicity in experimental animals. It may also be used when there is inadequate evidence of carcinogenicity in humans but there is sufficient evidence of carcinogenicity in experimental animals. In some instances, an agent for which there is inadequate evidence of carcinogenicity in humans and less than sufficient evidence of carcinogenicity in experimental animals together with supporting evidence from mechanistic and other relevant data may be placed in this group. An agent may be classified in this category solely on the basis of strong evidence from mechanistic and other relevant data.

    Group 3: The agent is not classifiable as to its carcinogenicity to humans.

    This category is used most commonly for agents for which the evidence of carcinogenicity is inadequate in humans and inadequate or limited in experimental animals. Exceptionally, agents for which the evidence of carcinogenicity is inadequate in humans but sufficient in experimental animals may be placed in this category when there is strong evidence that the mechanism of carcinogenicity in experimental animals does not operate in humans. Agents that do not fall into any other group are also placed in this category. An evaluation in Group 3 is not a determination of non-carcinogenicity or overall safety. It often means that further research is needed, especially when exposures are widespread or the cancer data are consistent with differing interpretations.

    Group 4: The agent is probably not carcinogenic to humans.

    This category is used for agents for which there is evidence suggesting lack of carcinogenicity in humans and in experimental animals. In some instances, agents for which there is inadequate evidence of carcinogenicity in humans but evidence suggesting lack of carcinogenicity in experimental animals, consistently and strongly supported by a broad range of mechanistic and other relevant data, may be classified in this group.

    Definitions of evidence, as used in IARC Monographs for studies in humans

    The evidence relevant to carcinogenicity from studies in humans is classified into one of the following categories:

    Sufficient evidence of carcinogenicity:

    The Working Group considers that a causal relationship has been established between exposure to the agent and human cancer. That is, a positive relationship has been observed between the exposure and cancer in studies in which chance, bias and confounding could be ruled out with reasonable confidence. A statement that there is sufficient evidence is followed by a separate sentence that identifies the target organ(s) or tissue(s) where an increased risk of cancer was observed in humans. Identification of a specific target organ or tissue does not preclude the possibility that the agent may cause cancer at other sites.Limited evidence of carcinogenicity: A positive association has been observed between exposure to the agent and cancer for which a causal interpretation is considered by the Working Group to be credible, but chance, bias or confounding could not be ruled out with reasonable confidence.

    Telstra's electromagnetic energy (EME) research program

    Inadequate evidence of carcinogenicity:

    The available studies are of insufficient quality, consistency or statistical power to permit a conclusion regarding the presence or absence of a causal association between exposure and cancer, or no data on cancer in humans are available.

    Evidence suggesting lack of carcinogenicity:

    There are several adequate studies covering the full range of levels of exposure that humans are known to encounter, which are mutually consistent in not showing a positive association between exposure to the agent and any studied cancer at any observed level of exposure. The results from these studies alone or combined should have narrow confidence intervals with an upper limit close to the null value (e.g. a relative risk of 1.0). Bias and confounding should be ruled out with reasonable confidence, and the studies should have an adequate length of follow-up. A conclusion of evidence suggesting lack of carcinogenicity is inevitably limited to the cancer sites, conditions and levels of exposure, and length of observation covered by the available studies. In addition, the possibility of a very small risk at the levels of exposure studied can never be excluded.

    In some instances, the above categories may be used to classify the degree of evidence related to carcinogenicity in specific organs or tissues.

    1. 237 913 new cases of brain cancers (all types combined) occurred around the world in 2008 (gliomas represent 2/3 of these). Source: Globocan 2008
    2. 'Limited evidence of carcinogenicity': A positive association has been observed between exposure to the agent and cancer for which a causal interpretation is considered by the Working Group to be credible, but chance, bias or confounding could not be ruled out with reasonable confidence.
    3. 'Inadequate evidence of carcinogenicity': The available studies are of insufficient quality, consistency or statistical power to permit a conclusion regarding the presence or absence of a causal association between exposure and cancer, or no data on cancer in humans are available.
      1. 'Acoustic neuroma risk in relation to mobile telephone use: results of the INTERPHONE international case-control study' (the Interphone Study Group, in Cancer Epidemiology, in press)
      2. 'Estimation of RF energy absorbed in the brain from mobile phones in the Interphone study' (Cardis et al., Occupational and Environmental Medicine, in press)
      3. 'Risk of brain tumours in relation to estimated RF dose from mobile phones – results from five Interphone countries' (Cardis et al., Occupational and Environmental Medicine, in press)
      4. 'Location of Gliomas in Relation to Mobile Telephone Use: A Case-Case and Case-Specular Analysis' (American Journal of Epidemiology, May 24, 2011.
  • The June 2011 and updated Oct 2014 WHO Fact Sheet (Number 193) on mobile phones and health, which takes into consideration the IARC categorisation, states; 

    “A large number of studies have been performed over the last two decades to assess whether mobile phones pose a potential health risk. To date, no adverse health effects have been established as being caused by mobile phone use.”

    The WHO also notes that further study into the long term use of mobile phones and cancer, and the effect of mobile phone use on young people should be undertaken.

    Cancer Council Australia Update on the IARC Classification

    WHO Research Database

    The WHO maintains an extensive database of scientific research into the effects of EME, including studies on the effects of radiofrequencies on public health.

    The WHO database, which is available on the WHO website, shows that there are more than 1900 published scientific articles on the biological and health effects of radiofrequency electromagnetic fields, and more than 630 studies on radiofrequencies specifically used by mobile phone networks.

Top

Help

  • Contact us
  • Support
  • Find a store
  • Check for outages
  • Troubleshoot an issue
  • Consumer advice
  • Financial hardship

  • Contact us
  • Support
  • Find a store
  • Check for outages
  • Troubleshoot an issue
  • Consumer advice
  • Financial hardship

About

  • About us
  • Careers
  • Partners and causes
  • Investors
  • Sitemap

  • About us
  • Careers
  • Partners and causes
  • Investors
  • Sitemap

Privacy and terms

  • Critical Information Summaries
  • Our customer terms
  • Your information
  • Privacy
  • Our website terms

  • Critical Information Summaries
  • Our customer terms
  • Your information
  • Privacy
  • Our website terms

Other Telstra sites

  • Telstra Wholesale
  • Global Enterprises & Services
  • Telstra Media
  • Telstra Health
  • Telstra Plus

  • Telstra Wholesale
  • Global Enterprises & Services
  • Telstra Media
  • Telstra Health
  • Telstra Plus

Find us

  • Facebook
  • Twitter
  • Instagram
  • YouTube

Shop by brand